Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

786 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of osteoanabolic agents (teriparatide and romosozumab) with bisphosphonates in prevention of subsequent vertebral fractures in patients treated for osteoporotic vertebral fracture for 12 months: An observational cohort study.
Maruo K, Kusukawa T, Toi M, Yamaura T, Hatano M, Oishi H, Nagao K, Arizumi F, Kishima K, Yoshie N, Tachibana T. Maruo K, et al. Among authors: toi m. Bone Rep. 2024 Apr 12;21:101762. doi: 10.1016/j.bonr.2024.101762. eCollection 2024 Jun. Bone Rep. 2024. PMID: 38650912 Free PMC article.
Prostaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells.
Punyawatthananukool S, Matsuura R, Wongchang T, Katsurada N, Tsuruyama T, Tajima M, Enomoto Y, Kitamura T, Kawashima M, Toi M, Yamanoi K, Hamanishi J, Hisamori S, Obama K, Charoensawan V, Thumkeo D, Narumiya S. Punyawatthananukool S, et al. Among authors: toi m. Nat Commun. 2024 Nov 1;15(1):9464. doi: 10.1038/s41467-024-53706-3. Nat Commun. 2024. PMID: 39487111 Free PMC article.
Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.
Tokunaga E, Iwata H, Itoh M, Taira T, Toyama T, Mizuno T, Osaki A, Yanagita Y, Nakamura S, Nakamura R, Sambe T, Ozaki T, Schiavon G, Howell SJ, Toi M. Tokunaga E, et al. Among authors: toi m. Breast Cancer. 2024 Oct 8. doi: 10.1007/s12282-024-01640-z. Online ahead of print. Breast Cancer. 2024. PMID: 39379782
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.
Nishimura T, Velaga R, Masuda N, Kawaguchi K, Kawaguchi S, Takada M, Maeshima Y, Tanaka S, Kikawa Y, Kadoya T, Bando H, Nakamura R, Yamamoto Y, Ueno T, Yasojima H, Ishiguro H, Morita S, Ohno S, Haga H, Matsuda F, Ogawa S, Toi M. Nishimura T, et al. Among authors: toi m. Cancer Sci. 2024 Dec;115(12):3928-3942. doi: 10.1111/cas.16339. Epub 2024 Oct 7. Cancer Sci. 2024. PMID: 39375938 Free PMC article.
786 results